Argent Trust Co Lowers Stock Holdings in Amgen Inc. $AMGN

Argent Trust Co lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 29.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,826 shares of the medical research company’s stock after selling 9,070 shares during the quarter. Argent Trust Co’s holdings in Amgen were worth $6,159,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Laurel Wealth Advisors LLC lifted its stake in shares of Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after acquiring an additional 6,676,575 shares during the period. Norges Bank purchased a new position in Amgen during the second quarter worth about $1,663,726,000. Vanguard Group Inc. lifted its position in Amgen by 1.6% in the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after purchasing an additional 841,117 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after purchasing an additional 687,735 shares during the period. Finally, Panagora Asset Management Inc. boosted its holdings in Amgen by 367.4% in the 2nd quarter. Panagora Asset Management Inc. now owns 490,457 shares of the medical research company’s stock valued at $136,940,000 after purchasing an additional 385,517 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on AMGN shares. HSBC reissued a “buy” rating and set a $425.00 target price on shares of Amgen in a research note on Wednesday, December 10th. BMO Capital Markets raised their target price on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Guggenheim boosted their target price on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Piper Sandler increased their price target on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Finally, TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $351.76.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported a new evolocumab bioavailability study that refines dosing/PK assessment for its PCSK9 cholesterol franchise, signaling management’s continued investment in a long‑lived cardiovascular product line and potential lifecycle optimization. Amgen Fine-Tunes Evolocumab
• Positive Sentiment: Amgen advanced maridebart (cafraglutide) toward a Phase 2b obesity and liver‑fat trial — news that expands the company’s obesity pipeline and supports upside potential beyond core biologics. Pipeline progress tends to lift pharma multiples. Amgen Advances Maridebart
• Positive Sentiment: Coverage and momentum narratives are supportive — Zacks highlights AMGN as a top long‑term momentum stock, which can attract trend‑driven and fund flows. Why Amgen is a Top Momentum Stock
• Positive Sentiment: Market headlines note AMGN reaching an all‑time high and outperforming the Dow recently — reinforcement for bullish sentiment and potential technical buying. Amgen stock hits all-time high Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Biotech sector activity: a large biotech IPO (Generate Biomedicines) indicates healthy capital markets for life sciences, which can be a neutral tailwind for large biotech names but doesn’t directly change Amgen’s fundamentals. Generate caps a strong month for biotech IPOs
• Neutral Sentiment: Minor portfolio rebalancing: a small sale by Bradley Foster & Sargent reduced a modest position in AMGN — not material to shares outstanding or sentiment. Bradley Foster & Sargent sells AMGN
• Negative Sentiment: Policy risk: a proposed U.S. bill to tighten rules on corporate inversions mentions AMGN among companies potentially affected by changes to international tax treatment — could raise longer‑term tax/structural uncertainty if enacted. Impact is uncertain and likely small near term. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported short‑interest data in feeds looks inconsistent (zeros/NaN) and should be treated with caution; no clear signal from short interest trends. (data sources above).

Amgen Stock Performance

Shares of AMGN opened at $388.16 on Friday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $390.14. The stock has a market cap of $209.25 billion, a P/E ratio of 27.28, a PEG ratio of 3.76 and a beta of 0.46. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company has a 50-day moving average of $348.89 and a two-hundred day moving average of $319.48.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the company posted $5.31 EPS. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.